Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Ivan De Dios"'
Autor:
Maher Albitar, Hong Zhang, Andrew Pecora, Stanley Waintraub, Deena Graham, Mira Hellmann, Donna McNamara, Ahmad Charifa, Ivan De Dios, Wanlong Ma, Andre Goy
Publikováno v:
Breast Cancer: Basic and Clinical Research, Vol 17 (2023)
Background: Homologous recombination deficiency (HRD) is the hallmark of breast cancer gene 1/2 ( BRCA1/2 )-mutated tumors and the unique biomarker for predicting response to double-strand break (DSB)–inducing drugs. The demonstration of HRD in tum
Externí odkaz:
https://doaj.org/article/a4b6c138eca440cbb2517f8a68962e5c
Autor:
Andrew Ip, Alexandra Della Pia, Gee Youn (Geeny) Kim, Jason Lofters, James Behrmann, Dylon Patel, Simone Kats, Jeffrey Justin Estella, Ivan De Dios, Wanlong Ma, Andrew L. Pecora, Andre H. Goy, Jamie Koprivnikar, James K. McCloskey, Maher Albitar
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionCytogenetic analysis is important for stratifying patients with various neoplasms. We explored the use of targeted next generation sequencing (NGS) in detecting chromosomal structural abnormalities or copy number variations (CNVs) in pati
Externí odkaz:
https://doaj.org/article/841f74756f494596ab6c774a50e1ff13
Autor:
Hong Zhang, Muhammad A. Qureshi, Mohsin Wahid, Ahmad Charifa, Aamir Ehsan, Andrew Ip, Ivan De Dios, Wanlong Ma, Ipsa Sharma, James McCloskey, Michele Donato, David Siegel, Martin Gutierrez, Andrew Pecora, Andre Goy, Maher Albitar
Publikováno v:
The American Journal of Pathology. 193:51-59
Diagnosis and classification of tumors is increasingly dependent on biomarkers. RNA expression profiling using next-generation sequencing provides reliable and reproducible information on the biology of cancer. This study investigated targeted transc
Autor:
Ahmad Charifa, Hong Zhang, Andrew Pecora, Andrew Ip, Ivan De Dios, Wanlong Ma, Lori A. Leslie, Tatyana Feldman, Andre Goy, Maher Albitar
Publikováno v:
Journal of Medical Artificial Intelligence. 5:10-10
Autor:
Maher Albitar, Hong Zhang, Ahmad Charifa, Andrew Ip, Ivan De Dios, Wanlong Ma, James McCloskey, Michele Donato, David Samuel DiCapua Siegel, Stanley E. Waintraub, Martin Gutierrez, Andrew L Pecora, Andre Goy
Publikováno v:
Journal of Clinical Oncology. 40:3047-3047
3047 Background: Expressed RNA can capture mutations, changes in expression levels due to methylation, and provide information on cell of origin, growth, and proliferation status. We developed an approach to isolate fragmented RNA from peripheral blo
Autor:
Maher Albitar, Hong Zhang, Ahmad Charifa, Andrew Ip, Ivan De Dios, Wanlong Ma, James K. McCloskey, Michele Donato, David Samuel DiCapua Siegel, Stanley E. Waintraub, Martin Gutierrez, Andrew L Pecora, Andre Goy
Publikováno v:
Journal of Clinical Oncology. 40:3048-3048
3048 Background: Expressed RNA can capture mutations, gene fusions, and biomarker profiles. In principle, each abnormal cell has one copy of mutated gene, but numerous copies of mutated RNA. Cell-free RNA (cfRNA) is not used due to the assumption tha
Autor:
Hong Zhang, Maher Albitar, Muhammad Asif Qureshi, Mohsin Wahid, Ahmad Charifa, Aamir Ehsan, Andrew Ip, Ivan De Dios, Wanlong Ma, James McCloskey, Michele Donato, David Samuel DiCapua Siegel, Martin Gutierrez, Andrew L Pecora, Andre Goy
Publikováno v:
Journal of Clinical Oncology. 40:3018-3018
3018 Background: Diagnosis and classification of tumors is becoming increasingly dependent on biological and molecular biomarkers. RNA expression profiling using next generation sequencing (NGS) provides information on various biological and molecula
Autor:
Alexandar Tzankov, Maurilio Ponzoni, Wayne Tam, Miguel A. Piris, Ken H. Young, Feng Zhu, Babak Shahbaba, Carlo Visco, Michael Boe Møller, Bing Xu, April Chiu, Hongwei Zhang, Eric D. Hsi, Karen Dybkær, Yong Li, Benjamin M. Parsons, Hong Zhang, Govind Bhagat, Ivan De Dios, Zijun Y. Xu-Monette, Youli Zu, Jooryung Huh, Hua You, Maher Albitar, Fredrick B. Hagemeister, Jane N. Winter, J. Han van Krieken, Andrés J.M. Ferreri
Publikováno v:
Blood Advances, 4, 28-3404
Blood Adv
Xu-Monette, Z Y, Zhang, H, Zhu, F, Tzankov, A, Bhagat, G, Visco, C, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, E D, You, H, Huh, J, Ponzoni, M, Ferreri, A J M, Møller, M B, Parsons, B M, van Krieken, J H, Piris, M A, Winter, J N, Hagemeister, F B, Shahbaba, B, De Dios, I, Zhang, H, Li, Y, Xu, B, Albitar, M & Young, K H 2020, ' A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL ', Blood advances, vol. 4, no. 14, pp. 3391-3404 . https://doi.org/10.1182/bloodadvances.2020001949
Blood advances, vol 4, iss 14
Xu-Monette, Z Y, Zhang, H, Zhu, F, Tzankov, A, Bhagat, G, Visco, C, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, E D, You, H, Huh, J, Ponzoni, M, Ferreri, A J M, Møller, M B, Parsons, B M, Han van Krieken, J, Piris, M A, Winter, J N, Hagemeister, F B, Shahbaba, B, de Dios, I, Zhang, H, Li, Y, Xu, B, Albitar, M & Young, K H 2020, ' A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL ', Blood advances, vol. 4, no. 14, pp. 3391-3404 . https://doi.org/10.1182/bloodadvances.2020001949
Blood Advances, 4, 14, pp. 28-3404
Blood Adv
Xu-Monette, Z Y, Zhang, H, Zhu, F, Tzankov, A, Bhagat, G, Visco, C, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, E D, You, H, Huh, J, Ponzoni, M, Ferreri, A J M, Møller, M B, Parsons, B M, van Krieken, J H, Piris, M A, Winter, J N, Hagemeister, F B, Shahbaba, B, De Dios, I, Zhang, H, Li, Y, Xu, B, Albitar, M & Young, K H 2020, ' A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL ', Blood advances, vol. 4, no. 14, pp. 3391-3404 . https://doi.org/10.1182/bloodadvances.2020001949
Blood advances, vol 4, iss 14
Xu-Monette, Z Y, Zhang, H, Zhu, F, Tzankov, A, Bhagat, G, Visco, C, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, E D, You, H, Huh, J, Ponzoni, M, Ferreri, A J M, Møller, M B, Parsons, B M, Han van Krieken, J, Piris, M A, Winter, J N, Hagemeister, F B, Shahbaba, B, de Dios, I, Zhang, H, Li, Y, Xu, B, Albitar, M & Young, K H 2020, ' A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL ', Blood advances, vol. 4, no. 14, pp. 3391-3404 . https://doi.org/10.1182/bloodadvances.2020001949
Blood Advances, 4, 14, pp. 28-3404
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity of B-cell lymphoma. Cell-of-origin (COO) classification of DLBCL is required in routine practice by the World Health Organization classification for biological and therapeutic insights.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29cab6f4fba3f040d2a18798264b72db
http://hdl.handle.net/2066/222478
http://hdl.handle.net/2066/222478
Autor:
Andre Goy, Hong Zhang, Andrew Ip, Ivan De Dios, Jeffrey Estella, Tatyana Feldman, Andrew L. Pecora, Maher Albitar, Wanlong Ma, Lori A. Leslie
Publikováno v:
Blood. 138:4480-4480
Introduction: Liquid biopsy has been reported to be useful in predicting residual disease in patients with diffuse large B-cell lymphoma (DLBCL). Most of the studies focused on quantifying the level of circulating lymphoma-specific DNA. We explored t
Autor:
Andrew Ip, Andre Goy, Scott D. Rowley, Hong Zhang, Andrew L. Pecora, Ivan De Dios, Hyung C. Suh, Sukhdeep Kaur, Michele L. Donato, Wanlong Ma, Maher Albitar, Spiraggelos Antzoulatos
Publikováno v:
Blood. 138:2892-2892
Introduction: Acute graft-vs.-host disease (aGVHD) remains a major diagnostic and clinical problem in patients after allogenic hematopoietic stem cell transplant (HSCT). Finding biomarkers that play a role in aGVHD not only helps in predicting and di